<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02233751</url>
  </required_header>
  <id_info>
    <org_study_id>QST-14-004</org_study_id>
    <nct_id>NCT02233751</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Subcutaneous Testosterone Enanthate</brief_title>
  <official_title>An Open-Label Study to Evaluate the Pharmacokinetics of Testosterone Enanthate After Single-Dose Injection Via QuickShot® Testosterone in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Antares Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Antares Pharma Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of pharmacokinetics of subcutaneous testosterone enanthate
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of pharmacokinetics and safety profile of testosterone enanthate injected
      subcutaneously via auto-injector in healthy male volunteers
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The dose assignment was random among the enrolled participants.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Concentration (Cmax) for Serum Testosterone and Testosterone Enanthate</measure>
    <time_frame>Maximum serum concentrations occurring during an 8 days study window</time_frame>
    <description>Cmax = Maximum blood concentration (ng/dL) of TT=Total Testosterone and TE=Testosterone Enanthate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to Time t</measure>
    <time_frame>168 hrs</time_frame>
    <description>AUC(0-168h) (ng⋅hr/dL) = area under the concentration-time curve from time zero to Day 8 (1 week);</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to Infinity</measure>
    <time_frame>time zero to infinity</time_frame>
    <description>AUC(0-inf) (ng⋅hr/dL) = area under the concentration-time curve from time zero to infinity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax)(hr)</measure>
    <time_frame>The sample time of Cmax during a 168 hour sampling interval</time_frame>
    <description>tmax = Time to reach maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-life (t 1/2)(hr)</measure>
    <time_frame>168 hours</time_frame>
    <description>t 1/2 = Half-life is the time required for a concentration to reduce to half its initial value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance CL/F (L/hr)</measure>
    <time_frame>168 hours</time_frame>
    <description>Clearance - volume of plasma from which TT/TE is completely removed per unit time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vd/F (L)</measure>
    <time_frame>168 hours</time_frame>
    <description>Vd/F (L) = Apparent volume of distribution</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Testosterone enanthate auto-injector - 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone enanthate auto-injector - 50 mg (SC injection)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone enanthate auto-injector - 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Testosterone enanthate auto-injector- 200 mg (SC injection)</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Testosterone enanthate auto-injector</intervention_name>
    <description>Randomization then administration of combination product study medication according to group assignment</description>
    <arm_group_label>Testosterone enanthate auto-injector - 200 mg</arm_group_label>
    <arm_group_label>Testosterone enanthate auto-injector - 50 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male subjects, 18-55 years of age, inclusive, at the time of signing the
             informed consent;

          -  Body weight ≥50 kg and body mass index within the range 19-30 kg/m2, inclusive, at
             screening;

          -  Medically healthy subjects with clinically insignificant screening and check-in
             results (medical history, 12-lead electrocardiogram [ECG], physical examination, and
             laboratory tests); and

          -  Subjects who are able to understand and are willing and able to give their signed
             informed consent before any trial-related procedures are performed.

        Exclusion Criteria:

          -  Currently diagnosed or a history of asthma, urticarial, angioedema, anaphylaxis,
             atopic dermatitis, clinically significant abnormality of skin of the abdomen, cancer,
             diabetes, or any other clinically significant cardiovascular, respiratory, metabolic,
             renal, hepatic, gastrointestinal, hematological, dermatological, venereal,
             neurological, psychiatric, or other major disorders;

          -  History of benign prostate hypertrophy (BPH), prostate cancer, or abnormal prostate
             specific antigen (PSA) values;

          -  PSA level &gt; 3 ng/ml at screening;

          -  Presence or history of gastrointestinal, hepatic or renal disease, or any other
             condition (including surgery) known to interfere with the absorption, distribution,
             metabolism, or excretion of medicines;

          -  Systolic blood pressure outside the range of 90 to 140 mmHg, diastolic blood pressure
             outside the range of 40 to 90 mmHg, and/or pulse rate outside the range of 40 to 100
             beats per minute after one repeat at screening or check-in;

          -  Abnormal ECG at screening as judged by the Investigator;

          -  History of clinically significant drug and/or food allergies as determined by the
             Investigator;

          -  Allergy to sesame, sesame oil, or a history of hypersensitivity or idiosyncratic
             reaction to compounds related to the study drug

          -  Subjects undergoing current treatment with other androgens (i.e.
             dehydroepiandrosterone [DHEA]), anabolic steroids, other sex hormones, or drugs that
             interfere with the metabolism of testosterone (i.e. opioids, anastrozole, clomiphene,
             dutasteride, finasteride, flutamide, ketoconazole, spironolactone, and testolactone);

          -  Subjects treated within the past 12 months with estrogens, gonadotropin releasing
             hormone (GnRH) agonists, or growth hormone;

          -  Prescription, over the counter medications, vitamins, herbal and dietary supplements
             taken within 7 days or 5 half-lives (whichever is longer) prior to the dose of study
             medication and duration of the study;

          -  Positive screen for human immunodeficiency virus (HIV), hepatitis B, and/or hepatitis
             C at screening;

          -  Positive urine screen for drugs of abuse (amphetamine, barbiturates, benzodiazepines,
             cocaine, marijuana, methadone, methamphetamines, oxycodone, and opiates) or positive
             breath alcohol test at screening and check-in
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Jaffe, MD</last_name>
    <role>Study Director</role>
    <affiliation>Antares Pharma Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medpace Clinical Pharmacology Unit</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45227</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>September 2, 2014</study_first_submitted>
  <study_first_submitted_qc>September 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2014</study_first_posted>
  <results_first_submitted>December 19, 2017</results_first_submitted>
  <results_first_submitted_qc>January 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2019</results_first_posted>
  <last_update_submitted>January 18, 2019</last_update_submitted>
  <last_update_submitted_qc>January 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Adult Males</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Pharmacokinetics of single doses of Testosterone Enanthate administered via a drug-auto injector combination product in Healthy Male Subjects</recruitment_details>
      <pre_assignment_details>Two dose groups, Testosterone Enanthate 50 mg and Testosterone Enanthate 200 mg , were evaluated in parallel with 6 subjects in each dose group.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Testosterone Enanthate 50 mg</title>
          <description>Testosterone enanthate auto-injector
50 mg SC injection</description>
        </group>
        <group group_id="P2">
          <title>Testosterone Enanthate 200 mg</title>
          <description>Testosterone enanthate auto-injector
200 mg SC injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>In total, 12 subjects were administered study drug: 6 subjects received 50 mg SC QST and 6 subjects received 200 mg SC QST. There were no discontinuations in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Testosterone Enanthate 50 mg</title>
          <description>Testosterone enanthate auto-injector 50 mg</description>
        </group>
        <group group_id="B2">
          <title>Testosterone Enanthate 200 mg</title>
          <description>Testosterone enanthate auto-injector 200 mg</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.0" spread="11.54"/>
                    <measurement group_id="B2" value="37.5" spread="10.84"/>
                    <measurement group_id="B3" value="37.8" spread="10.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Concentration (Cmax) for Serum Testosterone and Testosterone Enanthate</title>
        <description>Cmax = Maximum blood concentration (ng/dL) of TT=Total Testosterone and TE=Testosterone Enanthate</description>
        <time_frame>Maximum serum concentrations occurring during an 8 days study window</time_frame>
        <population>Healthy normal male volunteers</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Enanthate 50 mg</title>
            <description>Testosterone enanthate auto-injector 50 mg</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Enanthate 200 mg</title>
            <description>Testosterone enanthate auto-injector 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) for Serum Testosterone and Testosterone Enanthate</title>
          <description>Cmax = Maximum blood concentration (ng/dL) of TT=Total Testosterone and TE=Testosterone Enanthate</description>
          <population>Healthy normal male volunteers</population>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serum testosterone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="773.7" spread="121.26"/>
                    <measurement group_id="O2" value="1487.0" spread="405.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serum testosterone enanthate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.25" spread="6.90"/>
                    <measurement group_id="O2" value="267.33" spread="75.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to Time t</title>
        <description>AUC(0-168h) (ng⋅hr/dL) = area under the concentration-time curve from time zero to Day 8 (1 week);</description>
        <time_frame>168 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Enanthate 50 mg</title>
            <description>Testosterone enanthate auto-injector 50 mg</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Enanthate 200 mg</title>
            <description>Testosterone enanthate auto-injector 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to Time t</title>
          <description>AUC(0-168h) (ng⋅hr/dL) = area under the concentration-time curve from time zero to Day 8 (1 week);</description>
          <units>(ng⋅hr/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103731.5" spread="12591.81"/>
                    <measurement group_id="O2" value="176112.8" spread="47349.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6122.2" spread="929.12"/>
                    <measurement group_id="O2" value="33535.5" spread="9977.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to Infinity</title>
        <description>AUC(0-inf) (ng⋅hr/dL) = area under the concentration-time curve from time zero to infinity</description>
        <time_frame>time zero to infinity</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Enanthate 50 mg</title>
            <description>Testosterone enanthate auto-injector 50 mg</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Enanthate 200 mg</title>
            <description>Testosterone enanthate auto-injector 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to Infinity</title>
          <description>AUC(0-inf) (ng⋅hr/dL) = area under the concentration-time curve from time zero to infinity</description>
          <units>(ng⋅hr/dL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="279062.2" spread="35973.32"/>
                    <measurement group_id="O2" value="362627.4" spread="138773.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">AUC(0-inf) is not calculated when the constant lambda z is not assigned, which occurs if the terminal elimination phase is not linear, if the tmax is one of the 3 last data points, or if the regression coefficient is &lt;0.8.</measurement>
                    <measurement group_id="O2" value="62497.5" spread="24618.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Concentration (Tmax)(hr)</title>
        <description>tmax = Time to reach maximum concentration</description>
        <time_frame>The sample time of Cmax during a 168 hour sampling interval</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Enanthate 50 mg</title>
            <description>Testosterone enanthate auto-injector 50 mg</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Enanthate 200 mg</title>
            <description>Testosterone enanthate auto-injector 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax)(hr)</title>
          <description>tmax = Time to reach maximum concentration</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.51" spread="52.95"/>
                    <measurement group_id="O2" value="19.00" spread="7.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.01" spread="53.88"/>
                    <measurement group_id="O2" value="74.00" spread="57.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Half-life (t 1/2)(hr)</title>
        <description>t 1/2 = Half-life is the time required for a concentration to reduce to half its initial value</description>
        <time_frame>168 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Enanthate 50 mg</title>
            <description>Testosterone enanthate auto-injector 50 mg</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Enanthate 200 mg</title>
            <description>Testosterone enanthate auto-injector 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Half-life (t 1/2)(hr)</title>
          <description>t 1/2 = Half-life is the time required for a concentration to reduce to half its initial value</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261.73" spread="99.04"/>
                    <measurement group_id="O2" value="131.75" spread="28.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Half-life (t 1/2) is not calculated when the constant lambda z is not assigned, which occurs if the terminal elimination phase is not linear, if the tmax is one of the 3 last data points, or if the regression coefficient is &lt;0.8.</measurement>
                    <measurement group_id="O2" value="133.00" spread="67.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance CL/F (L/hr)</title>
        <description>Clearance - volume of plasma from which TT/TE is completely removed per unit time</description>
        <time_frame>168 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Enanthate 50 mg</title>
            <description>Testosterone enanthate auto-injector 50 mg</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Enanthate 200 mg</title>
            <description>Testosterone enanthate auto-injector 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance CL/F (L/hr)</title>
          <description>Clearance - volume of plasma from which TT/TE is completely removed per unit time</description>
          <units>L/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.07" spread="2.33"/>
                    <measurement group_id="O2" value="60.46" spread="21.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Clearance - CL/F is not calculated when the constant lambda z is not assigned, which occurs if the terminal elimination phase is not linear, if the tmax is one of the 3 last data points, or if the regression coefficient is &lt;0.8.</measurement>
                    <measurement group_id="O2" value="352.84" spread="127.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vd/F (L)</title>
        <description>Vd/F (L) = Apparent volume of distribution</description>
        <time_frame>168 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Testosterone Enanthate 50 mg</title>
            <description>Testosterone enanthate auto-injector 50 mg</description>
          </group>
          <group group_id="O2">
            <title>Testosterone Enanthate 200 mg</title>
            <description>Testosterone enanthate auto-injector 200 mg</description>
          </group>
        </group_list>
        <measure>
          <title>Vd/F (L)</title>
          <description>Vd/F (L) = Apparent volume of distribution</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6655.8" spread="1702.04"/>
                    <measurement group_id="O2" value="10959.5" spread="2040.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">Vd/F is not calculated when the constant lambda z is not assigned, which occurs if the terminal elimination phase is not linear, if the tmax is one of the 3 last data points, or if the regression coefficient is &lt;0.8.</measurement>
                    <measurement group_id="O2" value="62366.4" spread="23950.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 days</time_frame>
      <desc>Safety assessments included adverse events and injection site assessments.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment A</title>
          <description>Testosterone enanthate auto-injector (SC injection) Treatment A</description>
        </group>
        <group group_id="E2">
          <title>Treatment B</title>
          <description>Testosterone enanthate auto-injector (SC injections) Treatment B</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Jaffe, MD</name_or_title>
      <organization>Antares Pharma, Inc.</organization>
      <phone>609-359-3020</phone>
      <email>jjaffe@antarespharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

